

Subject: Reporting of histology cases

1. For the period **1st April 2023 to 31st March 2024**, please state which of the following arrangements were used for reporting histology cases which were not reported by employed or locum histopathologists during their contracted Programmed Activities (PAs). Please also state the amount spent in each category used.

	Method used (Y/N)	If yes, amount spent
a) Payment to own consultants for additional work outside contracted PAs	Y	£124,016
b) Payment directly to another Trust/ NHS provider, or consultants employed by another Trust/ NHS provider for reporting	N	0
c) Payment to a commercial company for reporting	Y	£170,793 <i>*based on date of invoice</i>

2. How many whole-time equivalent histopathology consultants (as defined by being on the GMC specialist register for pathology) were employed by the authority at **31st March 2024**:

Number of WTE histopathology consultants	7.85
---	------

3. How many histology cases were reported in the period **1st April 2023 to 31st March 2024**, overall and by the following sub-specialties

Specialty	Total reported histology cases 1st April 2023 to 31st March 2024
Dermatology	3,929
Gastro-intestinal	6,187
Urology	1,107
Gynaecology	4,587
Breast	1,362
Thoracic	515
Head and neck	880
Other	1,371
Total cases reported	19,938

4. How many of the total cases given above were reported by:

	Total reported histology cases 1st April 2023 to 31st March 2024
a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs.	16,060
b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work.	1,050
c. locum consultants working for the authority	193
d. external reporting companies. Please provide a total number of cases and the number reported by each of the following:	2,558
<ul style="list-style-type: none"> • Unilabs 	0
<ul style="list-style-type: none"> • HCA Laboratories including their subsidiary Backlogs 	0
<ul style="list-style-type: none"> • Source LD Path (previously Source Bioscience, and LD Path limited) 	2,426
<ul style="list-style-type: none"> • Cellular Pathology Services Limited 	0
<ul style="list-style-type: none"> • Diagnexia 	0
<ul style="list-style-type: none"> • Digital Pathology Partners 	0
<ul style="list-style-type: none"> • Cytel (including their subsidiary Pathognomics) 	0
<ul style="list-style-type: none"> • Poundbury Cancer Institute 	132
<ul style="list-style-type: none"> • Medica 	0
External reporting companies total	2,558

5. How much did the authority spend on each of the following during the period **1st April 2023 to 31st March 2024**:

	Amount spent 1st April 2023 to 31st March 2024
a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs. (salary plus NI plus pension contribution)	None
b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work.	£124,016
c. locum consultants working for the authority	None
d. external reporting companies. Please provide a total number of cases and the number reported by each of the following:	£170,793
• Unilabs	0
• HCA Laboratories including their subsidiary Backlogs	0
•	
• Source LD Path (previously Source Bioscience, and LD Path limited)	£137,079
• Cellular Pathology Services Limited	0
• Diagnexia	0
• Digital Pathology Partners	0
• Cytel (including their subsidiary Pathognomics)	0
• Poundbury Cancer Institute	£33,714
• Medica	
External reporting companies total	£170,793